FDA Drug Error Effort By Safety Office Builds On Existing Agency Activities
This article was originally published in The Tan Sheet
Executive Summary
FDA's new office of drug safety provides a formal structure for the agency's existing medication error activities, Office of Postmarketing Drug Risk Assessment Deputy Director Ralph Lillie told an Oct. 27 meeting of the Regulatory Affairs Professionals Society in Washington, D.C.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning